Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy

Journal of Medical Virology

Volumn 83, Issue 3, 2011, Pages 437-444

  Nicot, F ^a   Alric, L ^a,b   Barange, K ^c   Metivier S ^c   Dramard, J M ^d   Combis, J M ^e   Castan, B ^f   Meurisse, J J ^g   Payen, J L ^h   Garipuy, D ⁱ   Desmorat, H ^j   Peron, J M ^c   Thebault, S ^a   Morin, T ^k   Renou, C ^l   Barel, P ^m   Guerin, B ⁿ   Imbert, Y ^o   Sire, S ^p   Saune K ^a,b,q   Chatelut, E ^b,r   Izopet, J ^a,b,q   more..

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU PURPAN   (France)

^d Val d'Ariège Hospital   (France)

^e Ambroise Paré Clinic   (France)

^f Auch Hospital   (France)

^g Gastroenterology   (France)

^h Montauban Hospital   (France)

ⁱ Ducuing Hospital   (France)

^j Polyclinique du Parc   (France)

^k Bigorre Hospital   (France)

^l Hyeres Hospital   (France)

^m Albi Hospital   (France)

ⁿ Rodez Hospital   (France)

^o Agen Hospital   (France)

^p Cahors Hospital   (France)

^q INSERM   (France)

^r INSTITUT CLAUDIUS REGAUD   (France)

more..

Author keywords

HCV subtype; Hepatitis C; Ribavirin concentration

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 78851471617     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21976     Document Type: Article

References (47)

1. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, Tettoni C, Bonasso M, De Blasi T, D'Avolio A, Sciandra M, Siccardi M, Baietto L, Trentini L, Sinicco A, Cariti G, Di Perri G. 2008. The use of residual ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 61: 919-924.
2. Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kumada H. 2005. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 48: 138-144.
3. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. 2006. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086-1097.
4. Boulestin A, Kamar N, Legrand-Abravanel F, Sandres-Saune K, Alric L, Vinel JP, Rostaing L, Izopet J. 2004. Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C. Antimicrob Agents Chemother 48: 3610-3612.
5. Breilh D, Foucher J, Castera L, Trimoulet P, Djabarouti S, Merrouche W, Couzigou P, Saux MC, de Ledinghen V. 2009. Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 30: 487-494.
6. Cantaloube JF, Laperche S, Gallian P, Bouchardeau F, de Lamballerie X, de Micco P. 2006. Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France. J Clin Microbiol 44: 2051-2056.
7. Chen Z, Weck KE. 2002. Hepatitis C virus genotyping: Interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 40: 3127-3134.
8. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD. 2006. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470-477.
9. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. 2007. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45: 80-87.
10. Crespo M, Pou L, Esteban JI, Falco V, Ribera E, Lopez R, Sauleda S, Curran A, Villar del Saz S, Feijoo M, Ocana I, Pahissa A. 2007. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther 12: 1217-1223.
11. Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH. 2007. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 47: 23-30.
12. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. 2006. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 44: 1675-1684.
13. Fried MW. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36: S237-S244.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
16. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
17. Halfon P, Trimoulet P, Bourliere M, Khiri H, de Ledinghen V, Couzigou P, Feryn JM, Alcaraz P, Renou C, Fleury HJ, Ouzan D. 2001. Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene). J Clin Microbiol 39: 1771-1773.
18. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. 2000. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 22: 555-565.
19. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. 2004. Ribavirin pharmacokinetics in renal and liver transplant patients: Evidence that it depends on renal function. Am J Kidney Dis 43: 140-146.
20. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. 2003. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 47: 124-129.
21. Legrand-Abravanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L, Izopet J. 2005. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 77: 66-69.
22. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hezode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoel M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poinard T, Payan C, Izopet J. 2009. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol 81: 2029-2035.
23. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. 2005. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41: 275-279.
24. Lopez-Cortes L, Valera-Bestard B, Gutierrez-Valencia A, Ruiz-Valderas R, Jimenez L, Arizcorreta A, Terron A, Viciana P. 2008. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients. Clin Pharmacol Ther 84: 573-580.
25. Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, Denis F, Lunel F, Cales P, Lefebvre A, Fauchais AL, Liozon E, Vidal E. 2008. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 47: 1453-1461.
26. Maeda Y, Kiribayashi Y, Moriya T, Maruhashi A, Omoda K, Funakoshi S, Murakami T, Takano M. 2004. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 26: 9-15.
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965.
28. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, Gonzalez A, Rockstroh J, Asensi V, Miralles P, Laguno M, Moreno L, Giron JA, Vogel M, Garcia-Samaniego J, Nunez M, Romero M, Moreno S, de la Cruz JJ, Soriano V. 2004. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: A European collaborative study. Clin Infect Dis 38: 128-133.
29. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. 2008. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 13: 607-611.
30. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827-1838.
31. Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, Vinel JP, Pasquier C, Izopet J. 2005. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 86: 107-114.
32. Nicot F, Legrand-Abravanel F, Lafont T, Dubois M, Saune K, Pasquier C, Chatelut E, Izopet J. 2008. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 80: 1523-1529.
33. Pearlman BL, Ehleben C, Saifee S. 2007. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46: 1688-1694.
34. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 138: 1331-1337.
35. Rendon AL, Nunez M, Romero M, Barreiro P, Martin-Carbonero L, Garcia-Samaniego J, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. 2005. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 39: 401-405.
36. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourliere M, Zarski JP, Roudot-Thoraval F. 2007. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 14: 460-467.
37. Sandres-Saune K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. 2003. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 109: 187-193.
38. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462.
39. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74: 2391-2399.
40. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
41. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
42. Svensson JO, Bruchfeld A, Schvarcz R, Stahle L. 2000. Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. Ther Drug Monit 22: 215-218.
43. Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, Markatou M, Perelson AS. 2006. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43: 943-953.
44. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
45. Thomas F, Nicot F, Sandres-Saune K, Dubois M, Legrand-Abravanel F, Alric L, Peron JM, Pasquier C, Izopet J. 2007. Genetic diversity of HCV genotype 2 strains in south western France. J Med Virol 79: 26-34.
46. Tsubota A, Hirose Y, Izumi N, Kumada H. 2003. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 55: 360-367.
47. Zeuzem S. 2004. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? Ann Intern Med 140: 370-381.